Floatz logo

FILGRASTIM

First Line Therapy

Chinese PLA General Hospitalprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

7 Active assets in the First Line Therapy cohort.

Asset / SponsorPhaseRating
Daunorubicin
Chinese PLA General Hospital
Phase 2CCC
Venetoclax
Chinese PLA General Hospital
Phase 2CCC
Cytosin-Arabinosid
Chinese PLA General Hospital
Phase 2CCC
AKLAVINE
Chinese PLA General Hospital
Phase 2CCC
Tucidinostat
Chinese PLA General Hospital
Phase 2CCC
Idarubicine
Chinese PLA General Hospital
Phase 2CCC
5-azacytidine
Chinese PLA General Hospital
Phase 2CCC

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →